Tags

Type your tag names separated by a space and hit enter

Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia.
J Control Release. 2019 12 28; 316:1-11.JC

Abstract

Androgenetic alopecia is a common form of scalp hair loss that affects men in their mid-twenties and increases with age. Finasteride (FNS) has been approved and used orally to treat androgenetic alopecia; however, systemic effects on other androgen-dependent tissues cause severe side-effects. To overcome these systemic effects and target hair follicles in the scalp only, numerous topical formulations of FNS have been developed and further combined with the solid microneedle (SMN) technique to create micro-channels in the skin, thus overcoming the skin barrier properties. However, low delivery efficiency and concerns over patient safety of SMNs remain major limitations of the treatment. In the present study, we developed a novel FNS delivery system comprising powder-carrying microneedles (PCMs), which is a patch-less and self-administered powder delivery technique that simultaneously overcomes the safety issues. This system could directly implant FNS inside the skin by encapsulating the FNS powder in the center of the PCMs. In addition, we introduced the concept of a diffusion enhancer for this system, which facilitated the dissolution and release of the implanted FNS powder to achieve its successful intradermal delivery. Using implanted FNS powder as a reservoir inside the skin, this novel system permitted sustained release of the implanted FNS powder for 3 days with only one application of FNS-PCMs. In addition, compared with the topical FNS-gel, the developed system showed a higher efficacy in promoting hair growth and increased the amount and density of hair while addressing the safety concerns. This approach has the potential to advance the field of transdermal drug delivery for any type of powdered drug in a wide variety of biomedical applications.

Authors+Show Affiliations

Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.Juvic Inc., 272 Digital-ro, Guro-gu, Seoul 08389, Republic of Korea.Department of Biotechnology, Building 123, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea; Juvic Inc., 272 Digital-ro, Guro-gu, Seoul 08389, Republic of Korea. Electronic address: hijung@yonsei.ac.kr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31689460

Citation

Kim, Suyong, et al. "Transdermal Finasteride Delivery Via Powder-carrying Microneedles With a Diffusion Enhancer to Treat Androgenetic Alopecia." Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 316, 2019, pp. 1-11.
Kim S, Eum J, Yang H, et al. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. J Control Release. 2019;316:1-11.
Kim, S., Eum, J., Yang, H., & Jung, H. (2019). Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. Journal of Controlled Release : Official Journal of the Controlled Release Society, 316, 1-11. https://doi.org/10.1016/j.jconrel.2019.11.002
Kim S, et al. Transdermal Finasteride Delivery Via Powder-carrying Microneedles With a Diffusion Enhancer to Treat Androgenetic Alopecia. J Control Release. 2019 12 28;316:1-11. PubMed PMID: 31689460.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. AU - Kim,Suyong, AU - Eum,Jaehong, AU - Yang,Huisuk, AU - Jung,Hyungil, Y1 - 2019/11/02/ PY - 2019/08/01/received PY - 2019/10/27/revised PY - 2019/11/01/accepted PY - 2019/11/7/pubmed PY - 2020/10/27/medline PY - 2019/11/6/entrez KW - Androgenetic alopecia KW - Dissolving microneedles KW - Finasteride KW - Lipophilic powder KW - Transdermal drug delivery SP - 1 EP - 11 JF - Journal of controlled release : official journal of the Controlled Release Society JO - J Control Release VL - 316 N2 - Androgenetic alopecia is a common form of scalp hair loss that affects men in their mid-twenties and increases with age. Finasteride (FNS) has been approved and used orally to treat androgenetic alopecia; however, systemic effects on other androgen-dependent tissues cause severe side-effects. To overcome these systemic effects and target hair follicles in the scalp only, numerous topical formulations of FNS have been developed and further combined with the solid microneedle (SMN) technique to create micro-channels in the skin, thus overcoming the skin barrier properties. However, low delivery efficiency and concerns over patient safety of SMNs remain major limitations of the treatment. In the present study, we developed a novel FNS delivery system comprising powder-carrying microneedles (PCMs), which is a patch-less and self-administered powder delivery technique that simultaneously overcomes the safety issues. This system could directly implant FNS inside the skin by encapsulating the FNS powder in the center of the PCMs. In addition, we introduced the concept of a diffusion enhancer for this system, which facilitated the dissolution and release of the implanted FNS powder to achieve its successful intradermal delivery. Using implanted FNS powder as a reservoir inside the skin, this novel system permitted sustained release of the implanted FNS powder for 3 days with only one application of FNS-PCMs. In addition, compared with the topical FNS-gel, the developed system showed a higher efficacy in promoting hair growth and increased the amount and density of hair while addressing the safety concerns. This approach has the potential to advance the field of transdermal drug delivery for any type of powdered drug in a wide variety of biomedical applications. SN - 1873-4995 UR - https://www.unboundmedicine.com/medline/citation/31689460/ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-3659(19)30622-4 DB - PRIME DP - Unbound Medicine ER -